Introduction to the indications and treatment scope of Erdafitinib/Bocco

Erdafitinib (Erdafitinib) is an oral small molecule inhibitor targeting fibroblast growth factor receptor (FGFR1-4). It is mainly used to treat advanced malignant tumors with FGFR gene mutations or fusions. Its research and development logic is to achieve anti-tumor effects by inhibiting the FGFR signaling pathway and blocking the proliferation, angiogenesis and survival signals of tumor cells.

Currently, the core indication for erdafitinib approved overseas is the treatment of locally advanced or metastatic urothelial cancer (a type of bladder cancer ) with FGFR2 or FGFR3 gene alterations. Such patients often have limited response to standard chemotherapy, and erdafitinib provides them with a new precision treatment method. In addition, the research scope of erdafitinib is constantly expanding, including cholangiocarcinoma, some gastric cancers, breast cancer and even some rare cancer types. As long as its genetic testing shows the presence of driver mutations or fusions in the FGFR pathway, it may become a potential indication in the future.

In clinical practice, genetic testing is usually required to confirm whether there are FGFR-related mutations or fusions in the patient's tumor before using erdafitinib. This is also an important manifestation of precision medicine. Compared with traditional treatment, this gene-guided medication model can significantly increase the possibility of patients benefiting from treatment and avoid blind medication.

It is worth noting that erdafitinib is currently on the market in China, but it has not yet been fully included in medical insurance reimbursement, which limits its clinical popularity to a certain extent. However, with policy promotion and the accumulation of more clinical evidence, erdafitinib is expected to be more widely used in China in the future. Overall, the indications of erdafitinib are gradually expanding. It is not only an important treatment drug for advanced bladder cancer, but may also become a new option for multiple refractory cancers.

Reference materials：https://www.balversa.com/